Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Total Non-Current Liabilities (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $16.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 21.88% to $16.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.6 million through Dec 2025, down 21.88% year-over-year, with the annual reading at $16.6 million for FY2025, 21.88% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $16.6 million at NRX Pharmaceuticals, down from $24.9 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $24.9 million in Q3 2025, with the low at $16.6 million in Q4 2025.